CAS NO: | 2180923-05-9 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
生物活性 | Lisaftoclax (compound 6) is a dualBcl-2andBcl-xlinhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibitsIC50values of 2 nM and 5.9 nM forBcl-2andBcl-xl, respectively[1]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | Lisaftoclax (compound 6) exhibits IC50values of 5.5 nM and 6.4 nM in Bcl-2 dependent RS4;11 cells and Bcl-xl dependent Molm13 cells[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 882.42 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C45H48ClN7O8S | ||||||||||||||||
CAS 号 | 2180923-05-9 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 250 mg/mL(283.31 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |